Millipore Sigma Vibrant Logo

70839 Origami™ B(DE3)pLysS Competent Cells - Novagen

View Products on Sigmaaldrich.com
70839
Ver precios y disponibilidad

Descripción

Replacement Information

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
70839-3
Comprobando disponibilidad...
Disponibilidad a confirmar
Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      Ampolla de plást. 0.4 ml
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      Solicitar precio
      Description
      OverviewOrigami™ B host strains carry the same mutations in trxB and gor as the original Origami strains, except that they are derived from a lacZY mutant of BL21 to enable precise control of expression levels by adjusting the concentration of IPTG. Thus the Origami B strains combine the desirable characteristics of BL21, Tuner™, and Origami strains in one strain background. The mutations in trxB and gor are selectable on kanamycin and tetracycline, respectively; therefore, these strains cannot be used with plasmids that can only selected with kanamycin or tetracycline. These strains also include the lon and ompT deficiences of BL21, which increase protein stability.

      DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.

      pLysS strains express T7 lysozyme, which further suppresses basal expression of T7 RNA polymerase prior to induction, thus stabilizing pET recombinants encoding target proteins that affect cell growth and viability.
      Genotype: F- ompT hsdSB(rB- mB-) gal dcm lacY1 ahpC (DE3) gor522:: Tn10 trxB pLysS (CamR, KanR, TetR)


      This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges MilliporeSigma to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.




      This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the 'EMD Product') requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com.
      Catalogue Number70839
      Brand Family Novagen®
      References
      Product Information
      Components
      Guaranteed efficiencyGuaranteed efficiency: > 2 x 10⁶ cfu/μg
      Quality LevelMQ100
      Applications
      Biological Information
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Multiple Toxicity Values, refer to MSDS
      Storage ≤ -70°C
      Do not freeze Ok to freeze
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      70839-3 07790788052836

      Documentation

      Origami™ B(DE3)pLysS Competent Cells - Novagen Certificados de análisis

      CargoNúmero de lote
      70839

      Folleto

      Cargo
      Competent Cell Brochure

      Citas

      Título
    • Megan M. Kibbey, et al. (2006) Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to IGF-1 binding. Molecular Pharmacology 69, 833-845.
    • James Flint, et al. (2005) Probing the mechanism of ligand recognition in family 29 carbohydrate-binding molecules. Journal of Biological Chemistry 280, 23718-23726.
    • Protocolos de usuario

      Cargo
      TB009 Competent Cells
      TB053 Academic and Non-profit Laboratory Assurance Letter

      Productos y aplicaciones relacionados

      Related Products

      Número de referencia Descripción  
      70836 Origami™ B Competent Cells - Novagen Precios y disponibilidad
      70837 Origami™ B(DE3) Competent Cells - Novagen Precios y disponibilidad
      70911 Origami™ B Competent Cell Set - Novagen Precios y disponibilidad

      Productos relacionados por: Brand Facete

      Categorías

      Life Science Research > Genomic Analysis > Transfection and Protein Expression > Bacterial Expression > Competent Cells for Expression